Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation

Immunological Investigations

Volumn 44, Issue 3, 2015, Pages 216-236

  Bahrambeigi, Vahid ^a,b   Ahmadi, Nafiseh ^a   Salehi, Rasoul ^b   Javanmard, Shaghayegh Haghjooy ^a,b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipose derived mesenchymal stem cell (ADSC); Interleukin 2 (IL2); Melanoma B16F10; T regulatory (Treg) cell

Indexed keywords

5' NUCLEOTIDASE; CD4 ANTIGEN; INTERLEUKIN 2; MELAN A;

ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; GENETICALLY MODIFIED ADIPOSE DERIVED MESENCHYMAL STEM CELL; HISTOLOGY; IMMUNOCOMPETENCE; IN VIVO STUDY; LUNG METASTASIS; MALE; MELANOMA CELL; MESENCHYMAL STEM CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECONDARY; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

ADIPOSE TISSUE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENETIC THERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84928029547     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2014.988719     Document Type: Article

References (66)

1. Ahmadzadeh M, Rosenberg SA. (2006). IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood, 107, 2409-14.
2. Atkins MB, Lotze MT, Dutcher JP, et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17, 2105-16.
3. Azzarone B, Pottin-Clemenceau C, Krief P, et al. (1996). Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells? Eur Cytokine Netw, 7, 27-36.
4. Bachmann MF, Oxenius A. (2007). Interleukin 2: From immunostimulation to immunoregulation and back again. EMBO Rep, 8, 1142-8.
5. Bahrambeigi V, Ahmadi N, Ghafarizadeh AA, et al. (2013). Non-viral gene transfer into murine adipose derived mesenchymal stem cells: A comparative study of different non-viral methods. Gene Ther Mol Biol, 15, 164-75.
6. Bassi EJ, Moraes-Vieira PM, Moreira-Sa CS, et al. (2012). Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes, 61, 2534-45.
7. Bexell D, Gunnarsson S, Tormin A, et al. (2009). Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther, 17, 183-90.
8. Blank C, Brown I, Peterson AC, et al. (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res, 64, 1140-5.
9. Boyano MD, Garcia de Galdeano A, Smith-Zubiaga I, Canavate ML. (1997). IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. Anticancer Res, 17, 1135-41.
10. Boyman O, Purton JF, Surh CD, Sprent J. (2007). Cytokines and T-cell homeostasis. Curr Opin Immunol, 19, 320-6.
11. Boyman O, Sprent J. (2012). The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol, 12, 180-90.
12. Brandenburg S, Takahashi T, de la Rosa M, et al. (2008). IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol, 38, 1643-53.
13. Brusko TM, Putnam AL, Bluestone JA. (2008). Human regulatory T cells: Role in autoimmune disease and therapeutic opportunities. Immunol Rev, 223, 371-90.
14. Bubenik J. (2004). Interleukin-2 therapy of cancer. Folia Biol (Praha), 50, 120-30.
15. de la Rosa M, Rutz S, Dorninger H, Scheffold A. (2004). Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol, 34, 2480-8.
16. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, et al. (2012). Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med, 12, 574-91.
17. Dillman RO. (1994). The clinical experience with interleukin-2 in cancer therapy. Cancer Biother, 9, 183-209.
18. Dillman RO. (1999). What to do with IL-2? Cancer Biother Radiopharm, 14, 423-34.
19. Djouad F, Plence P, Bony C, et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 102, 3837-44.
20. Doucet C, Meazza R, Pottin-Clemenceau C, et al. (1997). Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient. Melanoma Res, 2, 7-17.
21. Ebrahimi A, Rahim F. (2014). Recent immunomodulatory strategies in transplantation. Immunol Invest, 43, 829-37.
22. Francisco LM, Salinas VH, Brown KE, et al. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med, 206, 3015-29.
23. Gaffen SL, Liu KD. (2004). Overview of interleukin-2 function, production and clinical applications. Cytokine, 28, 109-23.
24. Gao H, Priebe W, Glod J, Banerjee D. (2009). Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cellconditioned medium. Stem Cells, 27, 857-65.
25. Garcia de Galdeano A, Boyano MD, Smith-Zubiaga I, Canavate ML. (1996). B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor. Tumour Biol, 17, 155-67.
26. Garcia-Vazquez MD, Boyano MD, Canavate ML, et al. (2000). Interleukin-2 enhances the growth of human melanoma cells derived from primary but not from metastatic tumours. Eur Cytokine Netw, 11, 654-61.
27. Gerber SA, Sorensen EW, Sedlacek AL, et al. (2013). Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology, 138, 280-92.
28. Gurjal A, Philip AP. (2000). Interleukin-2 in cancer. Immunol Invest, 5, 273-85.
29. Han D, Pottin-Clemenceau C, Imro MA, et al. (1996). IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapy. Oncogene, 12, 1015-23.
30. Hara I, Nguyen H, Takechi Y, et al. (1995). Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer, 61, 253-60.
31. Hung SC, Deng WP, Yang WK, et al. (2005). Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res, 11, 7749-56.
32. Ives NJ, Stowe RL, Lorigan P, Wheatley K. (2007). Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol, 25, 5426-34.
33. Karnoub AE, Dash AB, Vo AP, et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557-63.
34. Keravala A, Ormerod BK, Palmer TD, Calos MP. (2008). Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase. J Neurosci Meth, 173, 299-305.
35. Kidd S, Spaeth E, Dembinski JL, et al. (2009). Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells, 27, 2614-23.
36. Komarova S, Kawakami Y, Stoff-Khalili MA, et al. (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther, 5, 755-66.
37. Lan RY, Selmi C, Gershwin ME. (2008). The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun, 31, 7-12.
38. Liao W, Lin JX, Leonard WJ. (2011). IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol, 23, 598-604.
39. Liao W, Lin JX, Leonard WJ. (2013). Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity, 38, 13-25.
40. Liu S, Ginestier C, Ou SJ, et al. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res, 71, 614-24.
41. Loebinger MR, Eddaoudi A, Davies D, Janes SM. (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res, 69, 4134-42.
42. Malek TR. (2008). The biology of interleukin-2. Annu Rev Immunol, 26, 453-79.
43. Martin FT, Dwyer RM, Kelly J, et al. (2010). Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat, 124, 317-26.
44. Matsuoka K, Koreth J, Kim HT, et al. (2013). Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med, 5, 179ra43.
45. McMillan DN, Kernohan NM, Flett ME, et al. (1995). Interleukin receptor expression and interleukin 2 localisation in human solid tumor cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer, 60, 766-72.
46. Munir S, Andersen GH, Svane IM, Andersen MH. (2013). The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology, 2, e23991.
47. Najar M, Raicevic G, Fayyad-Kazan H, et al. (2013). Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Int Immunopharmacol, 15, 693-702.
48. Niess H, Bao Q, Conrad C, et al. (2011). Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg, 254, 767-75.
49. Overwijk WW, Restifo NP. (2001). B16 as a mouse model for human melanoma. Curr Protoc Immunol Chapter 20: Unit 201, doi: 10.1002/0471142735.im2001s39.
50. Palomares T, Alonso-Varona A, Alvarez A, et al. (1997). Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Clin. Exp Metastasis, 15, 329-37.
51. Palomares T, Bilbao P, Alonso-Varona A, Barbera-Guillem E. (1995). The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma. Cancer Immunol Immunother, 40, 292-8.
52. Plaisance S, Rubinstein E, Alileche A, et al. (1993). Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer, 55, 164-70.
53. Ramasamy R, Lam EW, Soeiro I. (2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia, 21, 304-10.
54. Ren C, Kumar S, Chanda D, et al. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells, 26, 2332-38.
55. Rosenberg SA. (2001). Progress in human tumour immunology and immunotherapy. Nature, 411, 380-4.
56. Rosenberg SA, Mule JJ, Spiess PJ, et al. (1985). Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med, 161, 1169-88.
57. Schadendorf D, Vaubel J, Livingstone E, Zimmer L. (2012). Advances and perspectives in immunotherapy of melanoma. Ann Oncol, 23, 104-8.
58. Studeny M, Marini FC, Champlin RE, et al. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res, 62, 3603-8.
59. Sun T, Carr-Brendel V, De Zoeten EF, Cohen EP. (1998). Immunization with interleukin-2-secreting allogeneic cells transfected with DNA from mouse melanoma cells induces immune responses that prolong the lives of mice with melanoma. Cancer Gene Ther, 5, 110-18.
60. Swartz MA, Iida N, Roberts EW, et al. (2012). Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res, 72, 2473-80.
61. Tarhini AA, Agarwala SS. (2005). Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs, 6, 1234-9.
62. Waldmann TA. (2006). Effective cancer therapy through immunomodulation. Annu Rev Med, 57, 65-81.
63. West EE, Jin HT, Rasheed AU, et al. (2013). PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest, 123, 2604-15.
64. Yanez R, Lamana ML, Garcia-Castro J, et al. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24, 2582-91.
65. Yang W, Chen PW, Li H, et al. (2008). PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci, 49, 2518-25.
66. Zhang N, Bevan MJ. (2011). CD8(+) T cells: Foot soldiers of the immune system. Immunity, 35, 161-8.